AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Carasent

M&A Activity May 25, 2021

3568_rns_2021-05-25_f0abff77-4658-46c3-b1a8-716dccd758e5.html

M&A Activity

Open in Viewer

Opens in native device viewer

Carasent ASA: Carasent ASA acquires Metodika AB

Carasent ASA: Carasent ASA acquires Metodika AB

Carasent ASA: Carasent ASA acquires Metodika AB

Press release

May 25, 2021

Carasent ASA acquires Metodika AB

Carasent ASA has acquired the Swedish company Metodika AB (“Metodika”), a leading provider of

Enterprise Practice Management (EPM) solutions to independent hospitals and clinics across 10 European

countries.

We are very pleased to have completed this transaction as Metodika, with its complementary market

presence will expand Carasent’s geographical footprint significantly by giving access to new European

markets such as Denmark, Finland, UK, Germany and Italy, says Dennis Höjer, CEO of Carasent.

Metodika EPM software streamlines information management and efficiently helps its clients with handling

the day-to-day operations of clinics and hospitals. The product platform also includes a tool for inpatient

care that is complementary to Carasent’s current offering.

– We are impressed by the EPM solution that the Metodika team has developed and look forward to work

with its robust organization of 22 highly competent employees. The tool for treatment and surgery will

expand our product offering and enable us to service our clients in a new sub-segment. In summary, this

transaction is well in-line with communicated strategic priorities of expanding within geographical, segment

and product dimensions, he says.

Metodika has an attractive customer base of more than 50 clients across Europe. The company also has

growing SaaS-business that can be further intensified under Carasent ownership.

Metodika’s revenues and EBITDA were approximately SEK 28 million and SEK 2 million as per year-end

2020, with recurring revenues of approximately SEK 20 million. Metodika has delivered consistent historical

organic growth, with 10% revenue and 14% recurring revenue CAGR from 2013-2020. However, through

leveraging Carasent and Metodika’s combined scale and product offering in existing and new markets,

there are great opportunities to accelerate the growth going forward.

The purchase price will be SEK 114 million, corresponding to an enterprise value of SEK 108 million less

Metodika’s consolidated net cash position of SEK 6 million (the (“Purchase Price”).

The transaction purchase price will be settled as follows:

- ~80% of the Purchase Price in cash upon closing,

- ~20% of the Purchase Price as shares in Carasent valued at a price of NOK 39.1 per share,

corresponding to the 30-day VWAP at 20 May 2021 (the “Share Settlement”).

Danske Bank acted as financial advisor to Carasent in connection with the transaction.

Attached is an updated Company presentation.

Talk to a Data Expert

Have a question? We'll get back to you promptly.